Hederagenin suppresses glioma cell biological activities via Nur77 in vitro study. Issue 3 (7th December 2022)

• Record Type: Journal Article
• Authors: Dai, Yuxiang; Masra, Ngarmbaye; Zhou, Lu; Yu, Chen; Jin, Wei; Ni, Hongbin
• Is Part Of: Food science & nutrition. Volume 11:Issue 3(2023)
• Page Start: 1283
• Page End: 1296
• Publication Date: 2022-12-07
• Subjects: AKT -- glioma -- Hed -- Nur77 -- PI3K -- U251 -- U87; Food industry and trade -- Periodicals; Food -- Periodicals; Nutrition -- Periodicals; 664
• DOI: 10.1002/fsn3.3163
• Languages: English
• ISSNs: 2048-7177

Abstract

Abstract: The aim of this research was to discuss Hederagenin's antitumor effects on glioma by in vitro study. U251 and U87 cell lines were used as research target in our research. In the first step, the different Hed concentrations were treated to U251 and U87 cell lines, and the second step is Nur77 transfection in U251 and U87 with Hed treatment; measuring cell proliferation by MTT and EdU staining; evaluating cell invasion and migration abilities by transwell assay and relative gene and protein expressions by RT‐qPCR and WB assay. Compared with NC group, U251 and U87 cell proliferation were significantly depressed with cell apoptosis significantly increasing, and cell invasion and migration abilities were significantly inhibited in Hed‐treated groups ( p < .05, respectively); however, with Nur77 transfection, the Hed's antitumor effects disappeared. Meanwhile, with Hed supplement, Nur77, PI3K, and AKT gene expressions were significantly downregulated ( p < .05, respectively) in Hed‐treated groups; and Nur77, p‐PI3K, and p‐AKT protein expressions were significantly decreased ( p < .05, respectively) in Hed‐treated groups. Hed had antitumor effects on glioma cell biological activities via Nur77/PI3K/AKT pathway in vitro study. Abstract : Hed had antitumor effects on glioma cell biological activities via Nur77/PI3K/AKT pathway in vitro study.